# Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Source: https://onco.cc/key-papers/paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019/  
OnCo record `paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Review on CTLA-4 in Colorectal cancer, in Journal of experimental & clinical cancer research (2019), one of the most cited Europe PMC records with CTLA-4 in its title.

## Summary

Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer. Six drugs targeting PD-1 or its ligand PD-L1 and one drug targeting CTLA-4 have been approved for treatment of different types of cancers and several others are in advanced stages of development. The drugs when administered as monotherapy had dramatic increase in durable response rates and had manageable safety profile, but more than 50% of patients failed to respond to treatment. Combination of CTLA-4 and PD-1 blockers was then evaluated to increase the response rates in patients, and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) combination was shown to significantly enhance efficacy in metastatic melanoma patients. Subsequently, ipilimumab plus nivolumab was approved for treatment of metastatic melanoma, advanced renal cell carcinoma and metastatic colorectal cancer with MMR/MSI-H aberrations. The success of combination encouraged multiple clinical studies in other cancer types. Efficacy of the combination has been shown in a number of published studies and is under evaluation in multiple ongoing studies. This review aims to support future research in combination immunotherapy by discussing the basic details of CTLA-4 and PD-1 pathways and the results from clinical studies that evaluated combination of CTLA-4 and PD-1/PD-L1 blockers.

Indexed on Europe PMC as PubMed record 31196207 (DOI 10.1186/s13046-019-1259-z). Its title names CTLA-4 and its text names Colorectal cancer; PubMed types it as a review (review-article, Review). It was matched automatically to the idea "Making microsatellite-stable colorectal cancer immunotherapy-responsive" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Journal of experimental & clinical cancer research
- Year: 2019
- DOI: 10.1186/s13046-019-1259-z
- Authors: Rotte A
- What it means: One of the most cited reviews Europe PMC returns for CTLA-4 in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by CTLA-4 in the title and Colorectal cancer in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; A review summarises other studies; the primary reports it cites are the evidence.

## Sources

- J Exp Clin Cancer Res 2019: https://doi.org/10.1186/s13046-019-1259-z
- PubMed: https://pubmed.ncbi.nlm.nih.gov/31196207/
- Europe PMC: https://europepmc.org/article/MED/31196207

## Connected records

- journals: [Journal of experimental & clinical cancer research](https://onco.cc/journals/journal-of-experimental-and-clinical-cancer-research/)
- ideas: [Making microsatellite-stable colorectal cancer immunotherapy-responsive](https://onco.cc/ideas/idea-immunotherapy-mss-crc/)

---
JSON: https://onco.cc/api/v1/entities/paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019.json